Amy Barlow
Nurse Practitioner · Towson, MDNPI 1902861586
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,672 of the $5,812 with a category attached, or 80.4%. 37 manufacturers reported payments, led by Novo Nordisk at 29.1% of the total. Reporting peaked in 2021 at $1,529 and has fallen 56.2% since, to $669 in 2025. Among nurse practitioner clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 197 payments — averaging $29.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Sanofi-aventis U.S. LLC$676
- GSK$313
- AbbVie$304
- Lilly USA, LLC$282
- Corcept Therapeutics$229
- plus $2K from 31 others
What the payments were for
- Consulting fees$1,14020%
- Food & beverage$4,67280%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 42 | $1,693 |
| Sanofi-aventis U.S. LLC | 12 | $676 |
| GSK | 12 | $313 |
| AbbVie | 12 | $304 |
| Lilly USA, LLC | 13 | $282 |
| Corcept Therapeutics | 8 | $229 |
| Merck | 6 | $179 |
| Astellas Pharma US Inc | 3 | $171 |
| Novartis | 9 | $171 |
| AstraZeneca | 7 | $149 |
| Pfizer | 8 | $147 |
| Laborie Medical Technologies Corp. | 6 | $134 |
| Boehringer Ingelheim | 8 | $132 |
| Exact Sciences | 6 | $124 |
| Tandem Diabetes Care, Inc. | 1 | $123 |
| Abbott | 1 | $122 |
| Dexcom, Inc. | 6 | $88 |
| Amgen | 4 | $86 |
| Johnson & Johnson | 4 | $82 |
| Bayer | 3 | $71 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $63 |
| Esperion Therapeutics, Inc. | 4 | $61 |
| Blue Earth Diagnostics | 2 | $47 |
| Nevro Corp. | 2 | $45 |
| Boston Scientific | 2 | $43 |
| Kowa Pharmaceuticals America, Inc. | 1 | $36 |
| Vanda Pharmaceuticals Inc. | 1 | $29 |
| Jazz Pharmaceuticals Inc. | 1 | $28 |
| Currax Pharmaceuticals LLC | 2 | $27 |
| Almatica Pharma LLC | 1 | $26 |
| Tolmar, Inc. | 1 | $24 |
| Idorsia Pharmaceuticals US Inc | 1 | $20 |
| Biohaven Pharmaceuticals, Inc. | 1 | $20 |
| Amarin Pharma, Inc. | 1 | $19 |
| Sunovion Pharmaceuticals Inc. | 1 | $19 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBELSUS$1,140
- TZIELD$163
- SOLIQUA 100/33$159
- TOUJEO$138
- Korlym$125
- t:slim X2 Insulin Pump with Control-IQ$123
- Veozah$122
- FreeStyle Libre$122
- TRELEGY ELLIPTA$114
How this compares
$5,812 in reported general payments places this provider in the 95th percentile of 1,562 nurse practitioner providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 172 | $209,644 |
| OzempicSemaglutide | 140 | $181,358 |
| JardianceEmpagliflozin | 146 | $172,838 |
| TrulicityDulaglutide | 76 | $103,041 |
| FarxigaDapagliflozin Propanediol | 57 | $56,631 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 39 | $55,234 |
| Tresiba Flextouch U-200Insulin Degludec | 42 | $55,093 |
| JanuviaSitagliptin Phosphate | 20 | $32,212 |
| Tresiba Flextouch U-100Insulin Degludec | 31 | $26,689 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 58 | $21,884 |
| Victoza 3-PakLiraglutide | 18 | $21,450 |
| Humalog Kwikpen U-100Insulin Lispro | 35 | $15,459 |
| TradjentaLinagliptin | 13 | $12,973 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 15 | $12,552 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 17 | $11,197 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $282 | $312,685248 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr | $132 | $193,165171 claims |
| Novo NordiskOzempic | $1,693 | $181,358140 claims |
| AstraZenecaFarxiga | $149 | $56,63157 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $676 | $55,23439 claims |
| MerckJanuvia, Janumet Xr | $179 | $40,67636 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,562 nurse practitioner providers in Maryland.
Other nurse practitioner in Towson
- Robin HeeseTowson$8K
- Morgan GaleRockville$292K
- Sherilyn BrinkleyBaltimore$100K
- Michelle TurnerBaltimore$94K
- Nelli ZafmanLutherville$67K
- Ellen LancasterFallston$52K
- Doris TateEaston$34K
- Zeev NemirovskyBaltimore$19K
- Martha ReilleyAnnapolis$18K
- Stephanie ZwonitzerAnnapolis$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.